Doc7505
Diamond Member
- Feb 16, 2016
- 19,681
- 35,769
- 2,430
Ivermectin:
Could Population
-
Wide Distribution Have Prevented China’s Recent Mass COVID Outbreak?
China’s state-run medicare program recently failed to reach an agreement with Pfizer to import more Paxlovid, claiming the COVID-19 treatment drug is too expensive. This is despite the drug being offered to the state at a reduced rate in comparison with that offered to other developed countries. Lack of Paxlovid will leave only Azvudine, an anti-HIV drug the Chinese communist regime rushed through development and re-branded as an anti-COVID drug, as a treatment option.
Given the recent explosive spread of COVID and the resulting skyrocketing rates of hospitalization, finding viable treatment options is paramount.
Ivermectin in India and Peru
When the Delta variant broke out in 2021 across India, many states offered ivermectin population-wide. The efficacy of ivermectin in treating early and mild COVID-19 infections was confirmed in large states such as Uttar Pradesh—home to 241 million residents—where the use of the prophylactic dramatically reduced both the infection rate and the death toll.

**********

**********

Repurposing drugs, if successful, is the best accelerator for prophylactic development because it can save developers anywhere from three to 12 years as experts can reuse the data from previous clinical trials and other experiments.
A “wonder drug” like ivermectin should be strongly considered as a defense against viruses given its success both in mechanism studies and clinical trials as well as applications in a variety of diseases and infections. The suppression of ivermectin usage during the COVID-19 pandemic by government agencies and Big Pharma is one of the world’s most tragic events in modern medicine.
Commentary:
Herr Doktor Fauxceee would never have allowed such a scandalous publication.

Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns
The preprint endorsing ivermectin as a coronavirus therapy has been widely cited, but independent researchers find glaring discrepancies in the data
**********
**********

Study claiming that ivermectin reduces COVID-19 mortality by 92% has important methodological problems
The antiparasitic drug ivermectin has been subjected to many studies attempting to determine if it is effective at preventing or treating COVID-19. Large, randomized controlled trials so far haven’t detected benefits from ivermectin treatment in COVID-19 patients.